• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

Top 5 Asian Healthcare Stocks for 2021

Here are five picks in a sector whose private- and public-sector support is sure to continue as Asia ages.
By ALEX FREW MCMILLAN
Dec 18, 2020 | 10:00 AM EST
Stocks quotes in this article: JD, BABA

Health care has obviously dominated the world's attention in 2021. Having gained a short-term shot in the arm, private- and public-sector support for the sector is sure to continue in the years ahead, particularly as Asia ages.

Today, I'm highlighting five healthcare stocks to watch in Asia for 2021. This builds on Wednesday's Top 5 Asian Tech Stocks for 2021, showcasing five smaller tech companies in Asia worth a look; and Monday's Top 5 Asian Consumer Stocks for 2021, spotlighting five consumer-related plays that stand to gain in the year ahead as Asia recovers from Covid-19.

JD Health International (HK:6618)

Online health clinics are a new and booming business in China. Fears about contracting the coronavirus have driven patients online, looking for remote care rather than wandering the halls of a crowded hospital. There's still scope to explore profitable business models. China forecasts that its population of people over 60, already at 17%, will almost double by 2050.

The Chinese government is inventing the regulatory framework on the fly, which introduces a high degree of unpredictability. However, the Beijing government is likely to favor the largest players. It views stimulating online health care as a way to patch up the holes in the country's lacking healthcare system. The hope is that online medicine can serve rural and elderly populations better, providing access to better doctors. It should also reduce the strain on hospitals, which are the first destination at the moment even for people with minor maladies. Insurance reimbursement for online medical care is currently available only in a handful of cities, with the scheme due to be rolled out nationwide over the next two to three years.

JD Health, which launched in 2018 as a subsidiary of China's second-largest e-commerce platform, JD.com (JD) , already turns an impressive profit off its online pharmacy. It is the largest online retail pharmacy in China, with a 29.8% market share, according to Frost & Sullivan. JD Health had 72.5 million active users as of mid-year, the company says, up 35.5% in a year.

It says it hosts 100,000 daily online consultations. I'd imagine regulators will look at that business model, in which the company gets a commission from the fees doctors are able to extract from their patients/users. Frost & Sullivan also shows it is the largest online healthcare platform in China by revenue, with C¥10.8 billion (US$1.5 billion) in revenue last year.

The company conducted a US$3.5 billion initial public offering at the start of December, the largest in Hong Kong for the year, with the shares rising 56% for the day. The shares will join the burgeoning Hang Seng Tech Index as of Dec. 22.

The stock has continued that strong run and is now 111.1% above the offer price of HK$70.58. AliHealth is the competing offering from JD.com's competitor Alibaba Group Holding (BABA) . Full name Alibaba Health Information Technology (HK:0241), it has a U.S.-listed ADR under ALBBY. JD Health and AliHealth both benefit from feedthrough to drug purchases from the original e-commerce platform.

M3 (T:2413) and MTHRY

The pandemic has propelled the adoption of health tech and the shift to digital communications and operations in the healthcare industry. M3 launched LINE Healthcare in December 2019, which offers online consultations with doctors, and offered free Covid-19 sessions through June. Its AskDoctors online-consulting service has run since 2005.

On the industry side, it provides second opinions to doctors as well as career-related information on m3.com. The company has launched a platform, myMR-kun, to support online marketing from pharmaceuticals companies.

The LINE short-message app is the dominant one in Japan, with 83 million users. M3 works with about 280,000 doctors, or 90% of the total in Japan. What remains to be seen is if M3 can convert that heavy LINE use to one of its monthly subscription plans, with tiers at ¥1,000 (US$9) and ¥2,000 (US$18).

Covid has certainly driven a surge not just in online medical examinations for health conditions but also online medical consultations for the general public. M3 hopes to use its cloud-based electronic patient record system to launch an Artificial Intelligence-driven disease-prediction service. It also stands to gain from growth in its overseas clinical-trials business, which is able to expand faster with greater digitization of the process.

Nomura identifies it as the top pick in this sliver of the market, due to gain from greater deregulation. The company has also made good headway in cutting expenses this year.

Operating profits are forecast by Nomura to almost double from the ¥47.0 billion level in fiscal 2020, which ended in March, to ¥87.9 billion (US$809 million) for the fiscal year through March 2022. That's well ahead of the impressive 26.7% growth for the medical sector as a whole.

As a whole, profits show greater promise in health care, pharmaceuticals and video games than any other sector in Japan. Healthcare net income should by the 2022 tax year stand at 224% of 2018 levels, the highest in any industry. Pharma earnings should be up 163%. (Games and amusement profits should be at 219% of 2018 levels).

Gakken Holdings (T:9470)

Gakken is a publishing company that has long had an arm in medical textbooks, journals and online learning for nurses. It now aims to improve its digital offering and create an educational infrastructure linking local communities and, for instance, residents of long-term care facilities, which it also develops. Its stated aim is to promote a society that sees people live a healthy life "from 0 to 100" through the use of Gakken's digital version of comprehensive community health care.

Gakken develops serviced centers both for long-term care and for child care, and bought the home care operating group Medical Care Services in 2018. It is working with local governments to develop the "Gakken Community-based Integrated Care System," locating serviced accommodation in appropriate places to serve Japan's ageing population, and near health-care-related facilities such as clinics and pharmacies.

It plans to widen its own adoption of "digital transformation" in delivering long-term care and healthcare consumer education. Gakken is working with the Artificial Intelligence technology of its partner Fronteo, with which it has a capital and business alliance, to introduce behavior prediction and dementia prevention into the long-term care of elderly people. Its educational materials and sessions aim to prevent cognitive decline.

This is an industry-leader position, and should also lead to gains in margins and efficiency. Gakken also scores high in terms of social responsibility for the utility of its materials, community outreach and inclusive hiring.

Sysmex (T:6869) and SSMXY

Medical-equipment maker Sysmex stands to gain from the incoming Biden administration. Its medical hardware includes hematology analyzers used for blood tests in basic medicine. The company is due to introduce its next generation of such devices in 2021. Sysmex will also likely launch amyloid beta blood tests to identify Alzheimer's disease in the early stages.

Biden's plan to widen the scope of public health insurance should support broader adoption of equipment like that from Sysmex, and a substantial reduction in the burden of health insurance on middle-income households. This would set it apart from Obamacare in 2014. Biden's progress may be impeded by the U.S. Senate, however, if it remains in Republican hands.

Sysmex has also formed a joint venture with Kawasaki Heavy Industries (KWHIY), Japan's very first robot-making company, to develop medical robots. The j.v., called Medicaroid, is working on a robot to assist during surgery. The Japanese government gave that industry fresh impetus in 2018 by expanding insurance coverage from two robot-assisted surgical procedures to 14 treatments in fields such as pulmonology, gynecology and gastrointestinal surgery.

Ramsay Health Care (ASX:RHC) and RMYHY

Ramsay is the largest operator of private hospitals in Australia, accounting for 27% of private hospital beds. It also runs hospitals in Malaysia, Indonesia, Britain, France, Italy and Scandinavia.

Australia is an attractive investment market for health care, with relatively low levels of per-capita healthcare spending, which also looks low as a share of GDP. These absolute amounts will need to rise as the Australian population ages. The share of the population that is over 65 now stands at 15.9%, up from 12.3% in the last two decades, and set to increase as Baby Boomers continue to move past that mark. That generation (born 1945-1964) is about half-way through the transition.

Ramsay's business has, ironically, been disrupted by Covid-19, which led to increased operational costs. It should therefore show a strong rebound next year. Ramsay is the top Aussie healthcare pick for Jefferies, which estimates it has 21% to run in terms of share price.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, McMillan had no positions in any securities mentioned.

TAGS: Investing | Markets | Stocks | Trading | Healthcare | Asia | China | Australia | Japan

More from Stocks

Carnival's Valuation Is a Head Scratcher

Jonathan Heller
Jan 15, 2021 1:33 PM EST

Markets may be painting an overly rosy picture for the cruise ship company.

Beyond Meat May Simmer Down After Its Latest Rally

Bruce Kamich
Jan 15, 2021 12:56 PM EST

Has Thursday's rally made a significant change to the charts?

I Find Draganfly's Connection to American Airlines Intriguing

Timothy Collins
Jan 15, 2021 12:29 PM EST

Drones are set to become a bigger and bigger part of the commercial world and our day-to-day lives.

GameStop's Charts Show Us More Risk Than Reward

Bruce Kamich
Jan 15, 2021 12:04 PM EST

Let's check and see what clues we can glean from the charts and indicators.

An Undervalued Stock Yielding Over 6%

Bob Ciura
Jan 15, 2021 12:00 PM EST

With a high yield of 6.4%, this is an attractive stock for income investors.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 09:01 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    When it's time to sell, will you act or freeze?
  • 08:35 AM EST GARY BERMAN

    Wednesday Morning Fibocall for 1/13/2021

    Lower highs... SPX (Long-Term View) The 1/8/2...
  • 08:07 AM EST GARY BERMAN

    Tuesday Morning Fibocall for 1/12/2021

    Watch if the recent trend of lower highs continues...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login